These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 25252916)

  • 1. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
    Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
    Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.
    Zhang Z; Chen L; Wang H; Ahmad N; Liu X
    Cell Cycle; 2015; 14(13):2142-8. PubMed ID: 25927139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
    Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
    Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
    Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
    Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
    Pilling AB; Hwang C
    Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
    Edlind MP; Hsieh AC
    Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
    Li J; Wang R; Kong Y; Broman MM; Carlock C; Chen L; Li Z; Farah E; Ratliff TL; Liu X
    Mol Cancer Ther; 2017 Mar; 16(3):469-479. PubMed ID: 28069876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
    Hou X; Li Z; Huang W; Li J; Staiger C; Kuang S; Ratliff T; Liu X
    Prostate; 2013 Sep; 73(12):1352-63. PubMed ID: 23661607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality.
    Xu Y; Wang Q; Xiao K; Liu Z; Zhao L; Song X; Hu X; Feng Z; Gao T; Zuo W; Zeng J; Wang N; Yu L
    Mol Cancer Ther; 2020 Jun; 19(6):1221-1231. PubMed ID: 32220972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
    Shorning BY; Dass MS; Smalley MJ; Pearson HB
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL; Armstrong AJ
    Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.
    Lee SO; Lou W; Nadiminty N; Lin X; Gao AC
    Prostate; 2005 Jul; 64(2):160-7. PubMed ID: 15678501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).
    Li Z; Lu Y; Ahmad N; Strebhardt K; Liu X
    Cell Cycle; 2015; 14(19):3030-9. PubMed ID: 26292025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.
    Tortorella E; Giantulli S; Sciarra A; Silvestri I
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.